Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,021 people get BMRN articles and Market Currents by email alert.
Get email alerts on BMRN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (Mon, 9:00AM)
-
GlobeNewswire (May 16, 2013)
-
-
GlobeNewswire (May 14, 2013)
-
GlobeNewswire (May 2, 2013)
-
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
-
GlobeNewswire (Apr 18, 2013)
-
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
BioMarin's Expanding Product Portfolio Will Lead To Gains In 2013PropThink • Mon, Dec 31, 2012
-
-
What's To Come At BioMarinChimera Research Group • Thu, Aug 2, 2012 -
How Much Further Can Rare Diseases Carry BioMarin?Stephen Simpson • Thu, Mar 29, 2012 -
-
BioMarin Pipeline UpdateZacks Investment Research • Wed, Sep 1, 2010 -
BioMarin Rolls the Dice on a New Lupus DrugEben Tessari • Thu, Jan 8, 2009 -
Smallcap BioMarin's Drug Kuvan Showing Great PromiseNotable Calls • Tue, Feb 12, 2008 -
Look Who's Buying Shares of BioMarin PharmaceuticalLon Juricic • Tue, Jun 19, 2007 -
BioMarin Recieves Approval for Aldurazyme in JapanH.S. Ayoub • Wed, Nov 1, 2006
-
-
-
-
-
-
-
-
-
-
-
-
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19 -
-
-
-
-
7 High Growth Healthcare Stocks With Strong Inventory TrendsKapitall • Wed, Dec 12, 2012 -
-
-
BioMarin Pharmaceutical Inc. Q2 2009 Earnings Call TranscriptThu, Jul 30, 2009
-
BioMarin Pharmaceutical Inc., Q1 2009 Earnings Call TranscriptFri, May 1, 2009
-
BioMarin Pharmaceutical Inc. Q4 2008 Earnings Call TranscriptWed, Feb 18, 2009
-
BioMarin Pharmaceutical Inc. Q3 2008 Earnings Conference Call TranscriptTue, Oct 28, 2008
-
BioMarin Pharmaceutical, Inc. Q2 2008 Earnings Call TranscriptWed, Aug 6, 2008
-
BioMarin Pharmaceutical, Inc. Q1 2008 Earnings Call TranscriptWed, Apr 30, 2008
-
BioMarin Pharmaceutical, Inc. Q4 2007 Earnings Call TranscriptTue, Mar 4, 2008
-
GlobeNewswire (Mon, 9:00AM)
-
GlobeNewswire (May 16, 2013)
-
GlobeNewswire (May 14, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 18, 2013)
-
at CNBC.com (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 25, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
GlobeNewswire (Mar 19, 2013)
-
GlobeNewswire (Mar 19, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
at CNBC.com (Mar 15, 2013)
-
at CNBC.com (Feb 22, 2013)
-
GlobeNewswire (Feb 21, 2013)
BMRN vs. ETF Alternatives
Company Description
Currently, there's no company description for BMRN.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 25, 4:10 PM Biomarin Pharmaceuticals (BMRN): Q1 EPS of -$0.31 misses by $0.01. Revenue of $127.9M (+9.7% Y/Y) misses by $3.54M. Shares -1.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Thursday, April 25, 12:10 AM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
- Wednesday, April 24, 5:35 PM Notable earnings after Thursday’s close: AEM, ALTR, AMCC, AMKR, AMZN, BIDU, BJRI, BLDR, BMRN, CALX, CAMP, CB, CBG, CENX, CERN, CINF, CLWR, CRUS, CSTR, CTCT, DECK, DLB, ELY, EMN, EXPE, FII, FR, FSL, GERN, IGT, IM, INAP, INFA, KBR, KEG, KLAC, LEG, MCRS, MXIM, N, NR, NTGR, OLN, PFG, PKI, PMCS, QLIK, RMD, RRC, RSG, SBUX, SIMO, SPN, SWKS, SYNA, TCO, THRX, TLAB, UHS, VPRT, VRSN, WRE, WYNN Comment! [Earnings]
- Wednesday, April 24, 4:22 PM BioMarin (BMRN) submits a Marketing Authorization Application to the European Medicines Agency for its enzyme replacement therapy Vimizim. Earlier this month, the company submitted a Biologics License Application to the FDA for the treatment after positive Phase III clinical results. Comment! [Healthcare]
- Wednesday, March 20, 11:15 AM BioMarin Pharmaceutical (BMRN +0.7%) says results from Phase 1/2 trials for BMN-701, a treatment of late-onset Pompe disease, exceeded requirements for proceeding to the next phase of development. Pompe disease is a rare, inherited and often fatal disorder that disables the heart and skeletal muscles. The company plans to move on to Phase 2/3 trials for the treatment by the end of this year. Comment! [Healthcare, On the Move]
- Thursday, February 21, 4:09 PM BioMarin Pharmaceuticals (BMRN): Q4 GAAP EPS of -$0.43. Revenue of $132M beats by $2.3M. Shares +0.9% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 21, 12:10 AM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD Comment! [Earnings]
- Wednesday, February 20, 5:35 PM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD 2 Comments [Earnings]
- Tuesday, December 11, 2012, 2:02 PM Catalyst Pharmaceutical Partners (CPRX -2.4%) says it's issued 6,666,667 shares of its authorized but unissued common stock to BioMarin Pharmaceutical (BMRN +2.5%) upon the automatic conversion of a $5M loan that CPRX received from BMRN in October in connection with it's licensing of the North American rights to Firdapse. The shares were issued at a conversion price of $0.75 per share. Comment! [Healthcare, On the Move]
- Thursday, November 15, 2012, 2:07 PM Shares or BioMarin Pharmaceutical (BMRN -0.7%) spiked over 10% in a faction of a second at the open this morning, hitting a new 52-week high of $52.96 before triggering a trading pause by Nasdaq. The five-minute halt was activated after scores of trades were executed at sharply higher prices in a burst of high volume at 9:50 a.m. EST., possibly resulting from a "fat finger" trade-input error. On a separate note, the company is currently presenting an update at the Credit Suisse Healthcare Conference in Phoenix, AZ. Comment! [Healthcare]
-
Monday, November 5, 2012, 12:45 PM
Midday top 10 gainers: NVGN +50%. ICAD +43%. NTE +36%. HMNY +19%. BMRN +30%. OPTT +25%. VRNG +23%. EQU +15%. BEE +13%. BITA +12%.
Top 10 Losers: EBIX -22%. HGSH -19%. RDN -14%. PCYC -12%. MEAD -15%. VTUS -10%. PKBK -10%. COCO -9%. PGRX -9%. ENZ -9%. 1 Comment [On the Move] -
Monday, November 5, 2012, 9:10 AM
Premarket gainers: BMRN +28%. NTE +19%. NABI +12%. TRQ +10%. SOHU +9%. KBW +7%. ANTH +5%.
Losers: MTW -9%. RDN -9%. WYNN -6%. Comment! [On the Move] - Monday, November 5, 2012, 8:24 AM Biomarin (BMRN) rockets 29% after saying that its GALNS drug met its main target in a Phase III trial of improving the walking ability of patients with the rare genetic disorder of Morquio A Syndrome. The drug is seen as the most important in BioMarin's pipeline, with the potential to double its revenue. (PR) 1 Comment [Healthcare, On the Move]
- Wednesday, October 31, 2012, 3:02 PM Catalyst Pharmaceutical (CPRX -6.6%) slides after announcing a collaboration agreement with BioMarin Pharmaceutical (BMRN -4.5%) for the North American rights to Firdapse, a treatment of Lambert-Eaton Myasthenic Syndrome. According to the agreement, CPRX will license exclusive rights to Firdapse, while BMRN will make a $5M investment in CPRX for program advancement. Firdapse is an orphan product that has already been approved in the E.U. and is undergoing phase III clinical trials in the U.S. Comment! [Healthcare, On the Move]
- Thursday, October 25, 2012, 4:13 PM BioMarin Pharmaceutical (BMRN): Q3 EPS of -$0.04 beats by $0.16. Revenue of $128.1M (+13% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Thursday, October 25, 2012, 12:10 AM Notable earnings after Thursday’s close: AAPL, AMZN, APKT, BAS, BMRN, CA, CB, CERN, CINF, CLD, CLWR, COG, CRBC, CSTR, DECK, DV, EDR, EMN, EXPE, IM, INFA, KFN, KLAC, MXIM, MXWL, N, OLN, PFG, PWER, QLIK, RGC, SPF, VAR, VRSN, WRE, WWWW 2 Comments [Earnings]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.